BVSBioventus Inc.

$12.70+91% 1Y

$12.70

$6.5152 weeks$15.30

Is the price fair?

Good

Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 good, 2 without data

What the price assumes~−5% a yearderived · Jun 27, 2026

Priced for a decline (~−5% a year). The price demands less than its three-year revenue growth of 4% a year, expectations look modest.

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What BVS's price assumes

Bioventus Inc. trades at 16.5× earnings against 25.8× for the median Medical Devices name, cheaper than its own group.

16.5

Trailing P/E · Medical Devices median 25.8 · cheaper than the typical name in its group

Price / sales: 1.07
Price / sales · as of 2026-Q1
Free cash flow yield: 11%
Free cash flow yield · Medical Devices median 4.5%
Growth the price implies: −4.9%
Growth the price implies · The price pays for −4.9% free cash flow growth a year for a decade; the business has delivered +150% a year over the last three.